苯磺贝他斯汀治疗原发性获得性寒冷性荨麻疹的有效性研究

Research on the Effectiveness of Bepotastine Hesilate in the treatment of Primary Acquired Cold Urticaria

目的:评价苯磺贝他斯汀治疗原发性获得性寒冷性荨麻疹(PACU)的疗效与安全性。方法:将入选的PACU患者随机分为试验组和对照组,分别接受苯磺贝他斯汀和安慰剂治疗,疗程两周,观察患者对冷刺激试验的瘙痒程度和风团反应,以及冷水或冷空气刺激出现临床症状比较。结果:PACU患者对冷刺激试验的风团反应以及复温20min时的瘙痒程度,遇冷水或冷空气后出现风团反应和瘙痒程度与安慰剂组相比差异有统计学意义(P<0.05)。不良反应发生率低。结论:苯磺贝他斯汀治疗原发性获得性寒冷性荨麻疹安全、有效。

Objective: To evaluate the efficacy and safety of bepotastine besilate in the treatment of primary acquired cold urticaria( PACU). Method: The selected PACU patients were randomly divided into experimental group and control group,were treated with benzenesulfonyl bepotastine besilate and placebo treatment,treatment for two weeks of pruritus and wheal response to cold stimulation test were observed,and the cold water or cold air to stimulate the emergence of clinical symptoms. Result: The itchy wheal reaction cold stimulation test and rewarming in 20 min patients with PACU in cold water or air after the wheal reaction and pruritus compared with the placebo group had significant difference( P <0.05). The incidence of adverse reactions was low. Conclusion: Mizolastine is safe and effective in the treatment of primary acquired cold urticaria.